Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,933.9B | 7.0 | $438.3 12.8% undervalued | (5.8%) | $261.8B | $70.0B | 15.0% | 26.7% | 69.4% | 27.5% | 20.6% | |
$535.7B | 5.7 | $0.0 99.5% overvalued | (59.1%) | $216.7M | ($55.8M) | (2.9%) | (25.8%) | 57.1% | (27.0%) | 6.0% | |
$492.1B | 6.3 | $38.8 64.0% overvalued | 5.8% | $345.6B | $30.7B | 0.9% | 8.9% | 27.8% | 9.0% | 25.4% | |
$285.6B | 7.3 | $613.1 12.4% overvalued | (29.5%) | €28.3B | €9,084.6M | 2.6% | 32.1% | 51.3% | 25.2% | 19.9% | |
$213.0B | 6.2 | $139.1 10.8% overvalued | (3.4%) | $91.9B | $7,189.0M | 0.4% | 7.8% | 54.6% | 17.6% | 247.4% | |
$211.4B | 5.6 | $0.0 99.8% overvalued | (83.5%) | £16.2M | (£43.9M) | (42.1%) | (270.5%) | 44.8% | (1,274.8%) | 0.1% | |
$210.7B | 5.9 | $65.2 2.0% overvalued | 8.9% | $284.3B | $35.1B | (10.2%) | 12.3% | 19.0% | 13.8% | 42.8% | |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$196.8B | 7.5 | $524.5 19.0% undervalued | (22.4%) | $21.5B | $7,824.0M | 10.8% | 36.4% | 88.6% | 36.4% | 32.8% | |
$176.3B | 7.6 | $282.7 84.0% undervalued | (6.4%) | $40.7B | $12.7B | 12.1% | 31.3% | 56.0% | 42.4% | 54.2% | |
$172.0B | 6.8 | $603.6 0.4% undervalued | (9.5%) | $17.2B | $5,632.0M | 13.7% | 32.8% | 78.9% | 13.3% | 39.3% | |
$166.0B | 4.6 | $3.4 93.4% overvalued | (18.4%) | $11.8B | ($369.0M) | (15.9%) | (3.1%) | 37.6% | 4.9% | 76.0% | |
$164.8B | 7.1 | $234.3 29.4% overvalued | (0.8%) | $64.8B | $8,820.0M | (3.4%) | 13.6% | 36.1% | 22.7% | 197.0% | |
$164.7B | 7.0 | $130.4 32.8% undervalued | (52.2%) | $25.8B | $2,405.0M | 13.7% | 9.3% | 51.1% | 2.7% | 0.9% | |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$127.9B | 7.1 | $235.1 54.5% undervalued | (26.9%) | $27.6B | $5,935.0M | 4.3% | 21.5% | 47.7% | 36.4% | 33.6% | |
$114.6B | 5.8 | $108.4 17.0% undervalued | (15.3%) | $55.3B | $8,006.0M | (1.4%) | 14.5% | 30.5% | 11.2% | 37.5% | |
$113.4B | 6.9 | $166.8 40.1% overvalued | (4.9%) | $24.9B | $2,730.0M | 7.3% | 11.0% | 53.5% | 26.3% | 53.0% | |
$107.2B | 5.2 | $0.1 98.9% overvalued | (85.8%) | $112.1M | ($212.5M) | (9.1%) | (189.5%) | (32.0%) | (43.4%) | 0.4% | |
$106.7B | 5.2 | $672.8 48.9% undervalued | 6.6% | $71.0B | $5,287.0M | 5.1% | 7.4% | 9.9% | 16.2% | 10.2% |
Review premium stocks that beat benchmarks this week, offering consistent returns and stability.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the top weekly stock winners for 10 Mar 2025, outperforming the market and delivering gains.